Economies of resistance

References

• Anderson, M., Schulze, K., Cassini, A., Plachouras, D., & Mossialos, E. (2019). A governance framework for development and assessment of national action plans on antimicrobial resistance. The Lancet Infectious Diseases, 19(11), e371–e384. https://doi.org/10.1016/S1473-3099(19)30415-3
   PubMed Web of Science ®Google Scholar
• Antimicrobial Resistance Collaborators. (2022). Global burden of bacterial antimicrobial resistance in 2019. The Lancet, 399(10325), 629–655. https://doi.org/10.1016/S0140-6736(21)02724-0
   PubMed Web of Science ®Google Scholar
• Berman, D., Chandy, S. J., Cansdell, O., Moodley, K., Veeraraghaven, B., & Essack, S. Y. (2022). Global access to existing and future antimicrobials and diagnostics. The Lancet Global Health, 10(2), e293–e297. https://doi.org/10.1016/S2214-109X(21)00463-0
   PubMed Web of Science ®Google Scholar
• Boluarte, T., & Schulze, U. (2022, February 11). The case for a subscription model to tackle antimicrobial resistance. BCG. https://www.bcg.com/publications/2022/model-for-tackling-antimicrobial-resistancd
   Google Scholar
• Broom, A., Kenny, K., Kirby, E., Davis, M., Dodds, S., Post, J., & Broom, J. (2021). The modern hospital executive, micro improvements, and the rise of antimicrobial resistance. Social Science and Medicine, 285, 1–8. https://doi.org/10.1016/j.socscimed.2021.114298
   Web of Science ®Google Scholar
• Broom, A., Peterie, M., Kenny, K., Broom, J., Kelly-Hanku, A., Lafferty, L., Treloar, C., & Applegate, T. (2023). Vulnerability and antimicrobial resistance. Critical Public Health, 33(3), 308–317. https://doi.org/10.1080/09581596.2022.2123733
   Web of Science ®Google Scholar
• Broom, A., Peterie, M., Kenny, K., Ramia, G., & Ehlers, N. (2023). The administration of harm. Critical Social Policy, 43(1), 51–75. https://doi.org/10.1177/02610183221087333
   Web of Science ®Google Scholar
• Chandler, C. I. (2019). Current accounts of antimicrobial resistance. Palgrave Communications, 5(1), 1–13. https://doi.org/10.1057/s41599-019-0263-4
   Google Scholar
• Charmaz, K. (1990). ‘Discovering’ chronic illness. Social Science and Medicine, 30(11), 1161–1172. https://doi.org/10.1016/0277-9536(90)90256-r
   PubMed Web of Science ®Google Scholar
• Collyer, F., & White, K. (2011). The privatisation of medicare and the national health service, and the global marketisation of healthcare systems. Health Sociology Review, 20(3), 238–244. https://doi.org/10.1080/14461242.2011.11003086
   Web of Science ®Google Scholar
• Coukell, A. (2020, January 7). Antibiotics need a special place in the drug pricing debate. STAT. https://www.statnews.com/2020/01/07/antibiotics-need-a-special-place-in-the-drug-pricing-debate/
   Google Scholar
• D’Abramo, F. (2021). Antibiotic resistance, planetary health and the mimetic trap. Postcolonial Studies, 25(3), 321–339. https://doi.org/10.1080/13688790.2021.1963093
   Web of Science ®Google Scholar
• Dadgostar, P. (2019). Antimicrobial resistance. Infection and Drug Resistance, 12, 3903. https://doi.org/10.2147/IDR.S234610
   PubMed Web of Science ®Google Scholar
• Dall, C. (2019, April 16). Achaogen bankruptcy raises worry over antibiotic pipeline. CIDRAP. https://www.cidrap.umn.edu/news-perspective/2019/04/achaogen-bankruptcy-raises-worry-over-antibiotic-pipeline
   Google Scholar
• Emanuel, E. J. (2015, February 24). How to develop new antibiotics. New York Times. https://www.nytimes.com/2015/02/24/opinion/how-to-develop-new-antibiotics.html
   Google Scholar
• Falagas, M. E., Fragoulis, K. N., & Karydis, I. (2006). A comparative study on the cost of new antibiotics and other therapeutic drugs. PLoS ONE, 1(1), e11. https://doi.org/10.1371/journal.pone.0000011
   PubMed Web of Science ®Google Scholar
• Fojo, T., & Grady, C. (2009). How much is life worth. Journal of the National Cancer Institute, 101(15), 1044–1048. https://doi.org/10.1093/jnci/djp177
   PubMedGoogle Scholar
• Fowler, V. G., Jezek, A., Spivak, E. S., & Talkington, K. (2021). Urgent, comprehensive federal action needed to stem mortality and medicare costs associated with antimicrobial resistance. Clinical Infectious Diseases, 74(6), 1107–1111. https://doi.org/10.1093/cid/ciab697
   Web of Science ®Google Scholar
• Gabe, J., Harley, K., & Calnan, M. (2015). Healthcare choice. Current Sociology, 63(5), 623–635. https://doi.org/10.1177/0011392115590061
   Web of Science ®Google Scholar
• Ghandour, Z., Siciliani, L., & Straume, O. R. (2022). Investment and quality competition in healthcare markets. Journal of Health Economics, 82, 102588. https://doi.org/10.1016/j.jhealeco.2022.102588
   PubMed Web of Science ®Google Scholar
• Glover, R. E., Petticrew, M. P., Mays, N. B., & Thompson, C. (2023). How pharmaceutical and diagnostic stakeholders construct policy solutions to a public health ‘crisis’. Critical Public Health, 33(2), 197–206. https://doi.org/10.1080/09581596.2022.2026296
   Web of Science ®Google Scholar
• Glover, R. E., Singer, A. C., Roberts, A. P., & Kirchhelle, C. (2021). Nimble innovation. Lancet Microbe, 2(11), e637–e644. https://doi.org/10.1016/S2666-5247(21)00182-8
   PubMedGoogle Scholar
• Hall, W., McDonnell, A., & O’Neill, J. (2019). Superbugs. Harvard University Press.
   Google Scholar
• Hinchliffe, S., Butcher, A., & Rahman, M. M. (2018). The AMR problem. Palgrave Communications, 4(1), 1–12. https://doi.org/10.1057/s41599-018-0195-4
   Google Scholar
• Hofer, U. (2019). The cost of antimicrobial resistance. Nature Reviews Microbiology, 17(1), 3. https://doi.org/10.1038/s41579-018-0125-x
   PubMedGoogle Scholar
• Huffschmid, J. (2009). Finance as a driver of privatisation. In M. Frangakis, C. Hermann, J. Huffschmid, & K. Lóránt (Eds.), Privatisation against the European social model (pp. 49–60). Palgrave Macmillan.
   Google Scholar
• Kirby, E., Broom, A., Gibson, A., Broom, J., Yarwood, T., & Post, J. (2018). Medical authority, managerial power and political will: A bourdieusian analysis of antibiotics in the hospital. Health, 22(5), 500–518. https://doi.org/10.1177/1363459317715775
   PubMed Web of Science ®Google Scholar
• Kohut, M. R., Keller, S. C., Linder, J. A., Tamma, O. D., Cosgrove, S. E., Speck, K., Ahn, R., Dullabh, P., Miller, M. A., & Szymczak, J. E. (2020). The inconvincible patient. Family Practice, 37(2), 276–282. https://doi.org/10.1093/fampra/cmz066
   PubMed Web of Science ®Google Scholar
• Krachler, N., & Greer, I. (2015). When does marketisation lead to privatisation?. Social Science & Medicine, 124, 215–223. https://doi.org/10.1016/j.socscimed.2014.11.045
   PubMed Web of Science ®Google Scholar
• Krachler, N., Greer, I., & Umney, C. (2021). Can public healthcare afford marketization? Public Administration Review, 82(5), 876–886. https://doi.org/10.1111/puar.13388
   Google Scholar
• Lexchin, J. (2016). Private profit versus public policy. University of Toronto Press.
   Google Scholar
• Lübbert, C., Baars, C., Dayakar, A., Lippmann, N., Rodloff, A., Kinzig, M., & Sörgel, F. (2017). Environmental pollution with antimicrobial agents from bulk drug manufacturing industries in Hyderabad, South India, is associated with dissemination of extended-spectrum beta-lactamase and carbapenemase-producing pathogens. Infection, 45(4), 479–491. https://doi.org/10.1007/s15010-017-1007-2
   PubMed Web of Science ®Google Scholar
• Luepke, K. H., & Mohr, I. J. F. (2017). The antibiotic pipeline. Expert Review of Anti-Infective Therapy, 15(5), 425–433. https://doi.org/10.1080/14787210.2017.1308251
   PubMed Web of Science ®Google Scholar
• Luepke, K. H., Suda, K. J., Boucher, H., Russo, R. L., Bonney, M. W., Hunt, T. D., & Mohr, J. F., 3. (2017). Past, present, and future of antibacterial economics. Pharmacotherapy, 37(1), 71–84. https://doi.org/10.1002/phar.1868
   PubMed Web of Science ®Google Scholar
• Lu, J., Sheldenkar, A., & Lwin, M. O. (2020). A decade of antimicrobial resistance research in social science fields. Antimicrobial Resistance and Infection Control, 9(178), 1–13. https://doi.org/10.1186/s13756-020-00834-2
   PubMedGoogle Scholar
• Makary, M., Das, I., Hashim, F., & Walsh, C. (2021, January 20). The next pandemic is already here. MedPage Today. https://www.medpagetoday.com/opinion/marty-makary/90795
   Google Scholar
• Neri, M., Hampson, G., Henshall, C., & Towse, A. (2019, September 23). HTA and payment mechanisms for new drugs to tackle AMR. Office of Health Economics. https://www.ohe.org/publications/hta-and-payment-mechanisms-new-drugs-tackle-amr
   Google Scholar
• Pogge, T. (2005). Human rights and global health. Metaphilosophy, 36(1/2), 182–209. https://doi.org/10.1111/j.1467-9973.2005.00362.x
   Web of Science ®Google Scholar
• Sell, S. K., & Williams, O. D. (2020). Health under capitalism. Review of International Political Economy, 27(1), 1–25. https://doi.org/10.1080/09692290.2019.1659842
   Web of Science ®Google Scholar
• Singer, A. C., Kirchhelle, C., & Roberts, A. P. (2019). Reinventing the antimicrobial pipeline in response to the global crisis of antimicrobial-resistant infections. F1000research, 8(238), 1–6. https://doi.org/10.12688/f1000research.18302.1
   Google Scholar
• Singer, A. C., Kirchhelle, C., & Roberts, A. P. (2020). (Inter)nationalising the antibiotic research and development pipeline. The Lancet Infectious Diseases, 20(2), e54–e62. https://doi.org/10.1016/S1473-3099(19)30552-3
   PubMed Web of Science ®Google Scholar
• Statista. (2021, December). Revenue of the worldwide pharmaceutical market from 2001 to 2021. https://www.statista.com/statistics/263102/pharmaceutical-market-worldwide-revenue-since-2001/
   Google Scholar
• Taylor, J., Hafner, M., Yerushalmi, E., Smith, R., Bellasio, J., Vardavas, R., Bienkowska-Gibbs, T., & Rubin, J. (2014). Estimating the economic costs of antimicrobial resistance. RAND. https://www.rand.org/pubs/research_reports/RR911.html
   Google Scholar
• Timmermans, S., & Almeling, R. (2009). Objectification, standardization, and commodification in health care. Social Science and Medicine, 69(1), 21–27. https://doi.org/10.1016/j.socscimed.2009.04.020
   PubMed Web of Science ®Google Scholar
• Tobbell, D. (2011). Pills, power and policy. University of California Press.
   Google Scholar
• White, K., & Collyer, F. (1997). To market, to market. Australian Health Review, 20(2), 13–25. https://doi.org/10.1071/ah970013
   PubMedGoogle Scholar
• World Health Organization. (2015). WHO action plan on antimicrobial resistance. https://www.who.int/publications/i/item/9789241509763
   Google Scholar
• World Health Organization. (2019a). Antimicrobial stewardship programmes in health-care facilities in low- and middle-income countries. https://apps.who.int/iris/bitstream/handle/10665/329404/9789241515481-eng.pdf?sequence=1&isAllowed=y
   Google Scholar
• World Health Organization. (2019b). Ten threats to global health in 2019. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019
   Google Scholar
• World Health Organization. (2021). Global antimicrobial resistance and use surveillance system (GLASS) report. https://www.who.int/publications/i/item/9789240027336
   Google Scholar